Smoking cessation and nicotine addiction Market: Epidemiology, Therapies, Companies, DelveInsight | Achieve Life Sciences, NFL Biosciences SAS

Smoking cessation and nicotine addiction emerging therapies, such as Cytisinicline (cytisine), NFL-101, EMB-001, and others, are expected to boost the Smoking cessation and nicotine addiction Market in the upcoming years.

DelveInsight has launched a new report on "Smoking cessation and nicotine addiction - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Smoking cessation and nicotine addiction, historical and forecasted epidemiology as well as the Smoking cessation and nicotine addiction market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Smoking cessation and nicotine addiction market report @ https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Smoking cessation and nicotine addiction Market Report:

The highest number of prevalent smoking cessation cases was observed in the US, followed by the EU4, the UK, and Japan, while tobacco use was most widespread in the EU4 and the UK among these regions.
In 2023, the US led the 7MM (seven major markets) in terms of smoking cessation and nicotine addiction market size, reaching approximately USD 1,472 million. In contrast, Germany reported the smallest market at USD 46 million, though this figure is expected to rise by 2034.
The overall smoking cessation and nicotine addiction treatment market is projected to grow throughout the forecast period (2024-2034), driven by the introduction of new therapies such as cytisinicline, AXS-05, and NFL-101.
Based on DelveInsight estimates, the EU4 and the UK recorded the highest number of tobacco use cases in 2023, totaling approximately 63.95 million. This was followed by the US with around 50.89 million cases and Japan with roughly 20.19 million. These figures are projected to decline across the US, EU4, the UK, and Japan by 2034.
In the US in 2023, tobacco use was more prevalent among males, with about 31.04 million cases, compared to approximately 19.85 million cases among females.
In January 2025, the U.S. Food and Drug Administration (FDA) proposed a landmark rule to cap nicotine levels in cigarettes and other combustible tobacco products at 0.7 milligrams per gram of tobacco. This initiative aims to make these products minimally or non-addictive, potentially helping 19.5 million people quit smoking within five years and preventing over 48 million young people from starting. The rule is currently open for public comment and, if finalized, would take effect two years after publication.
In early 2025, the FDA approved the marketing of Zyn, a tobacco-free nicotine pouch product by Philip Morris International. Zyn is available in 10 flavors, including mint and coffee. The FDA's decision was based on evidence suggesting that Zyn poses fewer health risks compared to traditional cigarettes and smokeless tobacco products. However, concerns have been raised about the appeal of flavored nicotine products to youth.
Key Smoking cessation and nicotine addiction companies such as Achieve Life Sciences, NFL Biosciences SAS, and others are evaluating new drugs for Smoking cessation and nicotine addiction to improve the treatment landscape.
Promising Smoking cessation and nicotine addiction therapies include CHANTIX/ CHAMTIX (varenicline), ZYBAN (bupropion), Cytisinicline (cytisine), NFL-101, EMB-001, and others.

Smoking cessation and nicotine addiction Overview

Nicotine dependence involves a combination of behavioral, cognitive, and physical responses resulting from repeated tobacco use. It is characterized by a strong craving for tobacco, difficulty in limiting consumption, continued use despite negative effects, prioritization of tobacco over other interests, increased tolerance, and withdrawal symptoms. Tobacco-primarily consumed by smoking, chewing, or snorting-is the main source of nicotine, with cigarette smoking being the most common and harmful method. Contributing factors to nicotine addiction include weak enforcement of smoking restrictions, low awareness, limited motivation to quit, inadequate training for mental health professionals, and insufficient treatment options-especially in developing nations. Regular use of tobacco causes neuroadaptation and tolerance, and quitting often triggers withdrawal symptoms such as anxiety, irritability, increased appetite, and mood disturbances, all of which are further intensified by conditioned behaviors. These factors highlight the significant global health impact of tobacco dependence.

Smoking cessation and nicotine addiction Market Outlook

Effective treatment options for tobacco cessation include both behavioral interventions and FDA-approved medications. A range of products and services are currently available to aid in quitting smoking, as well as alternative nicotine products that are not specifically intended for cessation. Approved pharmacological treatments include various nicotine replacement therapies (NRTs), such as transdermal patches, gums, nasal sprays, oral inhalers, and lozenges.

The U.S. FDA has also approved two non-nicotine prescription medications for smoking cessation: CHANTIX (varenicline tartrate) and ZYBAN (bupropion hydrochloride), both available in tablet form. Generic versions of these medications have become available in recent years and are widely accessible in both the U.S. and European markets. In Japan, smoking cessation approaches include varenicline (marketed as CHAMPIX), nicotine replacement therapies, and some off-label treatments. However, bupropion-SR is not approved for smoking cessation in Japan.

Leading companies such as Achieve Life Sciences (Cytisinicline), Axsome Therapeutics (AXS-05), and NFL Biosciences (NFL-101) are actively developing new treatments. Their investigational therapies are in various stages of clinical trials, targeting smoking cessation and nicotine addiction.

Discover how the Smoking cessation and nicotine addiction market is rising in the coming years @ https://www.delveinsight.com/sample-request/smoking-cessation-and-nicotine-addiction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Smoking cessation and nicotine addiction Marketed Drugs
CHANTIX/ CHAMTIX (varenicline): Pfizer
ZYBAN (bupropion): GlaxoSmithKline
Smoking cessation and nicotine addiction Emerging Drugs
Cytisinicline (cytisine): Achieve Life Sciences
NFL-101: NFL Biosciences SAS
EMB-001: Embera NeuroTherapeutics, Inc.

Scope of the Smoking cessation and nicotine addiction Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Smoking cessation and nicotine addiction Companies: Achieve Life Sciences, NFL Biosciences SAS, and others
Key Smoking cessation and nicotine addiction Therapies: CHANTIX/ CHAMTIX (varenicline), ZYBAN (bupropion), Cytisinicline (cytisine), NFL-101, EMB-001, and others
Smoking cessation and nicotine addiction Therapeutic Assessment: Smoking cessation and nicotine addiction current marketed and Smoking cessation and nicotine addiction emerging therapies
Smoking cessation and nicotine addiction Market Dynamics: Smoking cessation and nicotine addiction market drivers and Smoking cessation and nicotine addiction market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Smoking cessation and nicotine addiction Unmet Needs, KOL's views, Analyst's views, Smoking cessation and nicotine addiction Market Access and Reimbursement

To know what's more in our Smoking cessation and nicotine addiction report, visit https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Smoking cessation and nicotine addiction Market Report:
Smoking cessation and nicotine addiction market report covers a descriptive overview and comprehensive insight of the Smoking cessation and nicotine addiction Epidemiology and Smoking cessation and nicotine addiction market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Smoking cessation and nicotine addiction market report provides insights into the current and emerging therapies.
The Smoking cessation and nicotine addiction market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Smoking cessation and nicotine addiction market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Smoking cessation and nicotine addiction market.

Got queries? Click here to know more about the Smoking cessation and nicotine addiction market Landscape https://www.delveinsight.com/sample-request/smoking-cessation-and-nicotine-addiction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Smoking cessation and nicotine addiction Patient Share (%) Overview at a Glance
5. Smoking cessation and nicotine addiction Market Overview at a Glance
6. Smoking cessation and nicotine addiction Disease Background and Overview
7. Smoking cessation and nicotine addiction Epidemiology and Patient Population
8. Country-Specific Patient Population of Smoking cessation and nicotine addiction
9. Smoking cessation and nicotine addiction Current Treatment and Medical Practices
10. Unmet Needs
11. Smoking cessation and nicotine addiction Emerging Therapies
12. Smoking cessation and nicotine addiction Market Outlook
13. Country-Wise Smoking cessation and nicotine addiction Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Smoking cessation and nicotine addiction Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Smoking cessation and nicotine addiction Market Outlook 2034 https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Smoking cessation and nicotine addiction Pipeline Insights, DelveInsight

"Smoking cessation and nicotine addiction Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Smoking cessation and nicotine addiction market. A detailed picture of the Smoking cessation and nicotine addiction pipeline landscape is provided, which includes the disease overview and Smoking cessation and nicotine addiction treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.